Physician profile
Ester Kohen
NPI 1376925032
$6,497.05
in general payments reported to CMS, 2019-2025
20 companies · $834 in 2025
The $834 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2021: $709 · 2022: $733 · 2023: $1,202 · 2024: $685 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Entertainment: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.89 |
| Entertainment | $191.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,261.07 | 2019-2022 | |
| Alcon Vision LLC | $787.14 | 2021-2025 | Dailies Total1, Precision 1, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $774.17 | 2019-2021 | |
| Coopervision INC. | $629.08 | 2023-2024 | Misight Contact Lens, Paragon Crt, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $344.37 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $288.76 | 2019-2021 | |
| Visioneering Technologies, INC. | $285.73 | 2019 | |
| Shire North American Group INC | $257.99 | 2019 | |
| Oyster Point Pharma, INC. | $216.82 | 2022 | |
| Bausch & Lomb Americas INC. | $209.87 | 2023-2025 | Infuse |
| Glaukos Corporation | $209.14 | 2021-2023 | |
| Optos, INC. | $191.36 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $189.23 | 2023-2024 | |
| Dompe US, INC. | $173.32 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $167.66 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $166.75 | 2023-2024 | Acuvue |
| Novartis Pharmaceuticals Corporation | $142.04 | 2019 | |
| Sun Pharmaceutical Industries INC. | $124.32 | 2019 | |
| Kala Pharmaceuticals, INC. | $63.85 | 2021-2022 | |
| Harrow Eye, LLC | $14.38 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ester Kohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.